These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36047997)

  • 41. A postzygotic NRAS mutation in a patient with Schimmelpenning syndrome.
    Kuroda Y; Ohashi I; Enomoto Y; Naruto T; Baba N; Tanaka Y; Aida N; Okamoto N; Niihori T; Aoki Y; Kurosawa K
    Am J Med Genet A; 2015 Sep; 167A(9):2223-5. PubMed ID: 25914220
    [No Abstract]   [Full Text] [Related]  

  • 42. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.
    Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309
    [No Abstract]   [Full Text] [Related]  

  • 43.
    Etemadmoghadam D; Azar WJ; Lei Y; Moujaber T; Garsed DW; Kennedy CJ; Fereday S; Mitchell C; Chiew YE; Hendley J; Sharma R; Harnett PR; Li J; Christie EL; Patch AM; George J; Au-Yeung G; Mir Arnau G; Holloway TP; Semple T; Pearson JV; Waddell N; Grimmond SM; Köbel M; Rizos H; Lomakin IB; Bowtell DDL; deFazio A;
    Cancer Res; 2017 Aug; 77(16):4268-4278. PubMed ID: 28646021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
    Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
    Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An NRAS mutation in a case of Erdheim-Chester disease.
    Aitken SJ; Presneau N; Tirabosco R; Amary MF; O'Donnell P; Flanagan AM
    Histopathology; 2015 Jan; 66(2):316-9. PubMed ID: 24754681
    [No Abstract]   [Full Text] [Related]  

  • 46. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
    Zhang H; Savage S; Schultz AR; Bottomly D; White L; Segerdell E; Wilmot B; McWeeney SK; Eide CA; Nechiporuk T; Carlos A; Henson R; Lin C; Searles R; Ho H; Lam YL; Sweat R; Follit C; Jain V; Lind E; Borthakur G; Garcia-Manero G; Ravandi F; Kantarjian HM; Cortes J; Collins R; Buelow DR; Baker SD; Druker BJ; Tyner JW
    Nat Commun; 2019 Jan; 10(1):244. PubMed ID: 30651561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melanoma brain metastases harboring BRAF
    Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
    J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
    Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
    BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.
    Charbel C; Fontaine RH; Malouf GG; Picard A; Kadlub N; El-Murr N; How-Kit A; Su X; Coulomb-L'Hermine A; Tost J; Mourah S; Aractingi S; Guégan S
    J Invest Dermatol; 2014 Apr; 134(4):1067-1074. PubMed ID: 24129063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
    Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
    BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer.
    Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
    Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).
    Capelli L; Casadei Gardini A; Scarpi E; Frassineti GL; Saragoni L; Puccetti M; Scartozzi M; Giannini M; Tamberi S; Corbelli J; Ulivi P
    Sci Rep; 2016 Nov; 6():37621. PubMed ID: 27886225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
    Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
    Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coexisting KRAS and NRAS mutations in colon cancer.
    Sorscher S
    J Clin Pathol; 2015 Dec; 68(12):1044. PubMed ID: 26243064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.